Views: 1,421 | Downloads:
19
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Paclitaxel and Carboplatin in Combination in the Treatment of Advanced Non-small-cell Lung Cancer (NSCLC) : A Preliminary Study
Ratanatharathorn V 
,
Jirajarus M ,
Sirachainan E ,
Sirilerttrakul S ,
Euaree A ,
Supatchaipisit P
,
Jirajarus M ,
Sirachainan E ,
Sirilerttrakul S ,
Euaree A ,
Supatchaipisit P This study was aimed to detennine the activity and toxtctty of combination paclitaxel
and carboplatin in stage III B and IV NSCLC. Eligibililty required performance status. Paclitaxel
was administered at a dose of 200 mgtm2, 3-hour infusion, followed by carboplatin at a
tartgeted area under the concentration-time curve (AUC) of 6. Treatment was repeated at 3-week
intervals for 6 courses. G-CSF 5 microgram/kg was subcutaneously injected during subsequent
courses if there was grade 3-4 leukopenia or granulocytopenia in the previous course. From
August 1996 through June 1997, 15 patients were enrolled. The median age was 47 years (range
20-68 years), 60 per cent were female. 73.3 per cent had adenocarcinoma, and 66.7 per cent had
stage III B disease. Eighty three courses were administered; 13 patients (86. 7%) completed all
six cycles. The objective response rate was 53.3 per cent, with 1 (6.7%) complete response and 7
(46.7%) partial responses. Pleural effusion, lung lesion and lymph node were the three most
common sites that responded to chemotherapy. Tht: major toxicity was myelosuppression. Grade
3 or 4 granulocytopenia, anemia and thrombocytopenia were observed in 18 per cent, 7.2 per cent
and 1.2 per cent, respectively, of 83 courses administered. Four episodes of febrile neutropenia
(4.8%) occurred in 3 patients. There was one episode of anaphylaxis during Paclitaxel infusion.
Other common toxicities were mild myalgia, paresthesias, alopecia and fatigue. Most of the
toxicities showed cumulative effect. Paclitaxel plus carboplatin is a moderately active regimen in
advanced NSCLC. Toxicities of this regimen are well tolerated.
and carboplatin in stage III B and IV NSCLC. Eligibililty required performance status. Paclitaxel
was administered at a dose of 200 mgtm2, 3-hour infusion, followed by carboplatin at a
tartgeted area under the concentration-time curve (AUC) of 6. Treatment was repeated at 3-week
intervals for 6 courses. G-CSF 5 microgram/kg was subcutaneously injected during subsequent
courses if there was grade 3-4 leukopenia or granulocytopenia in the previous course. From
August 1996 through June 1997, 15 patients were enrolled. The median age was 47 years (range
20-68 years), 60 per cent were female. 73.3 per cent had adenocarcinoma, and 66.7 per cent had
stage III B disease. Eighty three courses were administered; 13 patients (86. 7%) completed all
six cycles. The objective response rate was 53.3 per cent, with 1 (6.7%) complete response and 7
(46.7%) partial responses. Pleural effusion, lung lesion and lymph node were the three most
common sites that responded to chemotherapy. Tht: major toxicity was myelosuppression. Grade
3 or 4 granulocytopenia, anemia and thrombocytopenia were observed in 18 per cent, 7.2 per cent
and 1.2 per cent, respectively, of 83 courses administered. Four episodes of febrile neutropenia
(4.8%) occurred in 3 patients. There was one episode of anaphylaxis during Paclitaxel infusion.
Other common toxicities were mild myalgia, paresthesias, alopecia and fatigue. Most of the
toxicities showed cumulative effect. Paclitaxel plus carboplatin is a moderately active regimen in
advanced NSCLC. Toxicities of this regimen are well tolerated.
Download:
PDF